Altered Functional Connectivity in Pain-Related Brain Regions and Its Correlation with Pain Duration in Bone Metastasis with Cancer Pain
Table 2
Demographic and clinical characteristics.
CP+ ()
CP− ()
HC ()
value
Demographics
Age (years)
(45–76)
(48–73)
(44–74)
0.855
Gender (man : female)
18: 9
18: 9
18: 9
1.000
Education (years)
(0–16)
(4–12)
1 (0–20)
0.001
Anxiety SAS
(25–62)
(25–42)
(25–47)
0.069
Depression SDS
(25–70)
(25–43)
(25–62)
0.111
Clinical characteristics
Cancer stage, No. (%)
I
0
3 (11.11%)
NA
NA
II
0
1 (3.70%)
NA
NA
III
0
6 (22.22%)
NA
NA
IV
27 (100%)
17 (62.92%)
NA
NA
Subtype, No. (%)
NA
NA
Adenocarcinoma
16 (59.26%)
15 (55.56%)
NA
NA
Squama cancer
9 (33.33%)
10 (37.04%)
NA
NA
Sarcomatoid carcinoma
0
1 (3.70%)
NA
NA
Small cell cancer
2 (7.41%)
1 (3.70%)
NA
NA
Therapeutic regimen, No. (%)
NA
NA
Chemotherapy
21 (43.75%)
16 (53.33%)
NA
NA
Radiotherapy
10 (20.83%)
4 (13.33%)
NA
NA
Targeted therapy
10 (20.83%)
5 (16.67%)
NA
NA
Surgery
3 (6.25%)
5 (16.67%)
NA
NA
Immunotherapy
1 (2.08%)
0
NA
NA
Chinese medicinal therapy
3 (6.25%)
0
NA
NA
NRS
(1–7)
0
0
NA
Duration of cancer pain (days)
(20–2095)
NA
NA
NA
Note: values shown are (MIN–MAX) unless noted otherwise. Abbreviation: CP+: lung cancer patients with bone metastases suffering from cancer pain; CP−: lung cancer patients without pain-related complaints; HC: health controls; SD: standard deviation; MIN: minimum; MAX: maximum; BMI: body mass index; SAS: Self-Rating Anxiety Scale; SDS: Self-Rating Depression Scale; NA: not applicable.
